유전자 침묵 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 용도별, 제품 및 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Gene Silencing Market Growth & Trends:

The global gene silencing market size is expected to reach USD 21.29 billion by 2030 and is expected to grow at 13.8% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing significant growth due to increasing recognition of genetic disorders and urgent need for effective therapies. Over the past few years, advancements in gene silencing technologies, including RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based approaches, have led to breakthroughs in treating previously untreatable genetic diseases. As research intensifies, pharmaceutical and biotechnology companies are allocating more resources to developing gene silencing therapies to address the unmet medical needs of patients suffering from genetic conditions such as Huntington's disease, muscular dystrophy, and rare cancers. This growing demand for innovative, targeted therapies is a key driver for the market.

The COVID-19 pandemic, while disruptive in many areas, also highlighted the importance of gene-based therapies and accelerated the development of gene silencing technologies. During the pandemic, increased funding and collaboration between research institutions and pharmaceutical companies led to the rapid development of vaccine technologies, highlighting the potential of gene silencing strategies for tackling a wide range of diseases. In addition, the pandemic led to a greater focus on genetic research and innovation in drug discovery, driving the need for gene silencing solutions in areas such as viral infections, cancer treatment, and autoimmune disorders. As a result, gene silencing technologies have garnered more attention, positioning them as a critical component in the future of precision medicine.

Furthermore, the growing availability of gene silencing-related services has fueled market expansion. Contract research organizations (CROs) and contract manufacturing organizations (CMOs) have become integral partners for biotech and pharmaceutical companies developing gene silencing therapies. These service providers offer expertise in clinical trials, regulatory compliance, and scalable manufacturing, enabling faster and more cost-effective development of gene silencing-based drugs. The pandemic underscored the need for robust and scalable production systems, driving further demand for services that support gene therapy development. This trend is expected to continue as the pipeline for gene silencing products expands and as companies work to meet the increasing demand for these advanced therapeutic options.

Gene Silencing Market Report Highlights:

• By product & service, services is expected to witness the fastest growth with a CAGR of 14.2% during the forecast period. The complexity of gene silencing techniques has created a need for expert support in clinical trial management, regulatory guidance, and bioinformatics analysis. This rising demand for customized solutions and end-to-end services is fueling market expansion
• By application, the drug discovery & development segment dominated the market and captured the largest revenue share in 2024. Advances in high-throughput screening, bioinformatics tools, and genomic databases have enhanced target identification and validation processes and are expected to fuel global market growth
• By end use, the pharmaceutical & biotechnology companies segment dominated the market and accounted for the largest revenue share in 2024. The market is driven by the increasing focus on precision medicine and the potential of gene-based therapies to treat a wide range of genetic disorders, cancers, and rare diseases
• North America held the largest share of 48.23% in 2024. The presence of a population with high susceptibility to rare diseases, increased market penetration rates, and technologically advanced healthcare infrastructure support the region's growth
• A few of the key market players include Revvity, Inc., Danaher, Agilent Technologies, GenScript, Merck KGaA, Thermo Fisher Scientific, Inc., Illumina, Bio-Rad Laboratories, Bio-Techne, New England Biolabs, Inc.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Silencing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Genetic Disorders
    • 3.2.1.2. Technological Advancements in Delivery Systems
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Development Costs and Complex Manufacturing
    • 3.2.2.2. Regulatory and Ethical Challenges
• 3.3. Gene Silencing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Gene Silencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Gene Silencing Market Product & Service Movement Analysis
• 4.3. Global Gene Silencing Market Size & Trend Analysis, by Product & Service, 2018 - 2030 (USD Million)
• 4.4. Products
• 4.5. Products Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
  • 4.5.1. RNAi
    • 4.5.1.1. RNAi Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.1.2. miRNA
      • 4.5.1.2.1. miRNA Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.1.3. siRNA
      • 4.5.1.3.1. siRNA Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.1.4. Others
    • 4.5.1.5. Others Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. CRISPR-Cas9
    • 4.5.2.1. CRISPR-Cas9 Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.2. CRISPR Kits & Reagents
      • 4.5.2.2.1. CRISPR Kits & Reagents Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.3. CRISPR Libraries
      • 4.5.2.3.1. CRISPR Libraries Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.4. Others
    • 4.5.2.5. Others Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Antisense Oligonucleotides
    • 4.5.3.1. Antisense Oligonucleotides Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)

Chapter 5. Gene Silencing Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Gene Silencing Market Application Movement Analysis
• 5.3. Global Gene Silencing Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
• 5.4. Drug Discovery & Development
• 5.5. Drug Discovery & Development Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
  • 5.5.1. Neurology
    • 5.5.1.1. Neurology Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.2. Oncology
    • 5.5.2.1. Oncology Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.3. Infectious Diseases
    • 5.5.3.1. Infectious Diseases Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.4. Metabolic Diseases
    • 5.5.4.1. Metabolic Diseases Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Therapeutics Manufacturing
  • 5.6.1. Therapeutics Manufacturing Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 5.7. Agricultural Applications
  • 5.7.1. Agricultural Applications Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)

Chapter 6. Gene Silencing Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Gene Silencing Market End Use Movement Analysis
• 6.3. Global Gene Silencing Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & Biotechnology Companies Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & Research Institutes Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 6.6. CROs & CMOs
  • 6.6.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)

Chapter 7. Gene Silencing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Strategy Mapping
• 8.4. Participants Overview
  • 8.4.1. Revvity, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Danaher
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Agilent Technologies
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. GenScript
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Merck KGaA
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Thermo Fisher Scientific, Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Illumina
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Bio-Rad Laboratories
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Bio-Techne
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. New England Biolabs, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives